Tazarotene 0.045% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in Adult Males

January 2020 | Volume 19 | Issue 1 | Original Article | 78 | Copyright © January 2020


Published online December 13, 2019

aFran E. Cook-Bolden MD,ª Michael H. Gold MD,b Eric Guenin PharmD PhD MPHc

aMount Sinai Health System, New York, NY bTennnessee Clinical Research Center, Nashville, TN cOrtho Dermatologics, Bridgewater, NJ

21. Leyden JJ, Tanghetti EA, Miller B, et al. Once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.1% microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial. Cutis. 2002;69:12–19.

22. Dosik JS, Arsonnaud S. Tolerability comparison of adapalene gel, 0.3% versus tazarotene cream 0.05% in subjects with healthy skin. J Drugs Dermatol. 2007;6(6):632-638.

23. Kircik LH. Tretinoin microsphere gel pump 0.04% versus tazarotene cream 0.05% in the treatment of mild-to-moderate facial acne vulgaris. J Drugs Dermatol. 2009;8(7):650-654.

24. Webster GF, Guenther L, Poulin YP, et al. A multi-center, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1 % gel and adapalene 0.1 % gel for the treatment of facial acne vulgaris. Cutis. 2002; 69: 4–11

25. Shalita A, Miller B, Menter A, et al. Tazarotene cream versus adapalene cream in the treatment of facial acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. J Drugs Dermatol. 2005;4:153-158.

26. Tanghetti EA, Dhawan S, Green L, et al. Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris. J Drugs Dermatol. 2010;9(5):49-558.

27. Kerdel FA, Draelos ZD, Tyring SK, et al. A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a halobetasol propionate 0.01% lotion and halobetasol propionate 0.05% cream in the treatment of plaque psoriasis. J Dermatolog Treat. 2019;30(4):333-339.

28. Tanghetti AE, Werschler WP, Lain T, et al. Tazarotene 0.045% Lotion for Once- Daily Treatment of Moderate-to-Severe Acne Vulgaris: Results from two Phase 3 Trials. J Drugs Dermatol. 2019; in press.

29. Leyden J, Gold LS, Weiss J. Why topical retinoids are the mainstay of therapy for acne. Dermatol Ther. 2017;7(3):293-304.

30. Nast A, Dreno B, Bettoli V, et al. European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol. 2012;26(Suppl 1):1–29.

31. Thielitz A, Abdel-Naser MB, Fluhr JW, et al. Topical retinoids in acne–an evidence- based overview. J Dtsch Dermatol Ges. 2008;6:1023–1031.

32. Thielitz A, Helmdach M, Ropke EM, et al. Lipid analysis of follicular casts from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne agents. Br J Dermatol. 2001;145:19–27.

33. Grimes P, Callender V. Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double-blind, randomized, vehiclecontrolled study. Cutis. 2006;77:45–50.

34. Tanghetti E, Dhawan S, Green L, et al. Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris. J Drugs Dermatol. 2010;9:549–558.

AUTHOR CORRESPONDENCE

Fran E, Cook-Bolden MD dermdrcookbolden@gmail.com